The diet drug Ozempic...would you take it..?

hollydolly said:
A 'Godzilla' new weight loss jab created by the maker of Mounjaro could make patients shed dangerous amounts of weight, research has suggested.

Early trials of the drug, retatrutide, have already shown it can help people shed a quarter of their body weight in under a year — almost twice as effective as Ozempic.

But now scientists have discovered alarming complications of the drug-induced fat loss, like bone breakages and kidney problems.

Unlike other slimming injections, the jab manufactured by US pharmaceutical giant Eli Lilly not only suppresses the appetite but also speeds up the metabolism.

Yet, volunteers in the latest clinical trial have claimed they've lost too much fat too quickly.

One participant reportedly dropped 22 per cent of her weight in just nine months. She later began skipping every other dose regardless.

Another, who lost almost a third of his weight in eight months, developed potentially dangerous kidney stones.

On social media, users who claim to have got their hands on the experimental drug — despite it not yet being approved for use in either the US or UK — have also boasted of losing more than three stone on the jabs in a matter of months.

The once-weekly injectable has been dubbed 'triple g' because it targets three different hormones involved in how much we eat.

By comparison, Ozempic and Wegovy target one, and Mounjaro targets two hormones.

According to Stat News, it is not certain whether the trial participant who lost 30 per cent of his weight in eight months developed the kidney stone because of weight loss.

Studies, however, have suggested that such medicines, collectively known as GLP-1 agonists, may trigger the condition.

Another, who claimed his weight had plunged 31 per cent over a similar time period said he had been forced to eat calorie-dense foods like peanut butter to avoid losing more.

'Godzilla' weight loss jab beats Ozempic but has an alarming problem
Click to expand...
It's hard to take this seriously article when they start using the word "jab" in the first sentence. They have played up 2 negative outcomes, one person w kidney stones, and one broken hip which may or may not have happened anyway, while completely ignoring the positives. The article fails to explain why the drug is being developed allowing some to think this is just a new weight loss drug (like somehow having a proper body weight is somehow not something for every person to strive for.)

I will be the first to admit I can't define even half the words used in the study, but one word I do recognize is cirrhosis [of the liver] and another statement that is perfectly clear is there is no treatments for the disease, MALSD, this drug is being developed to treat.

Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial

"Nonalcoholic fatty liver disease, now termed metabolic dysfunction-associated steatotic liver disease (MASLD), is one of the most common chronic liver diseases in the world1,2. The global prevalence of MASLD has increased dramatically, from 25% in 1990–2006 to 38% in 2016–2019. Meta-regression analyses have demonstrated that the increased prevalence of obesity is a major contributor to the growing burden of MASLD2. At least half of patients with MASLD are estimated to have obesity3.

Insulin resistance is an important pathophysiologic driver for MASLD. Insulin resistance in adipocytes contributes to dysregulated lipolysis, resulting in excessive delivery of fatty acids to the liver. Substrate overload can drive hepatic de novo lipogenesis. Hepatic steatosis can trigger inflammation causing hepatocyte injury, apoptosis and necrosis, eventually leading to liver fibrosis, although numerous factors contribute to the heterogeneity of disease progression4. These features characterize the more progressive form of MASLD, which is called nonalcoholic steatohepatitis or metabolic dysfunction-associated steatohepatitis (MASH)1. Over the course of several years, worsening fibrosis may progress to cirrhosis, the development of portal hypertension and ultimately hepatic decompensation. By 2019, MASH became the second most common indication for liver transplant in the United States and was the fastest increasing indication5.

Currently, no treatments for MASH are approved in the United States or Europe. Many potential pharmacological therapies are in clinical development, harnessing several different mechanisms of action. Among these are the incretin-based therapies that target glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors and induce weight loss. Semaglutide, a GLP-1 receptor mono-agonist, is in phase 3 development for noncirrhotic MASH, having demonstrated histological improvements in a phase 2 MASH trial6. The GIP/GLP-1 dual agonist, tirzepatide, reduced liver fat and improved biomarkers of MASH and fibrosis in patients with type 2 diabetes (T2D); a phase 2 trial in MASH is ongoing7,8.

The addition of glucagon (GCG) agonist activity to GLP-1 agonism has shown promise for providing greater reduction of hepatic fat, an early marker of improvement in MASH. Efocipegtrutide (HM15211), a triple GLP-1/GIP/GCG receptor agonist, has demonstrated significant liver fat reduction after 12 weeks in participants with MASLD and is now in phase 2 development9,10.

Retatrutide (RETA; LY3437943) is a single protein conjugated to a fatty diacid moiety that activates human GIP, GLP-1 and GCG receptors. On the basis of cell culture studies, retatrutide is less potent than endogenous ligands of the human GCG and GLP-1 receptors (0.3 and 0.4 times as active, respectively) and is more potent at the human GIP receptor (by a factor of 8.9)11.

The pharmacokinetics of retatrutide are dose proportional; it has a half-life of approximately 6 days, enabling weekly subcutaneous administration12. In a phase 2 study of retatrutide in people with obesity who did not have T2D, a weight reduction up to 24.2% was observed after 48 weeks. Treatment was also associated with improvements in blood pressure (BP), lipids and glycemia13. In this Article, we report the results of a substudy of that trial that evaluated changes in liver fat and biomarkers of MASH and fibrosis in people with MASLD."
 

Last edited:
Pendle said:
What are MSM granules please?
I have arthritis in my spine & hip & take collagen.
I don’t have diabetes & am not overweight so wouldn’t take Ozempic
Click to expand...

It is natural not a drug but the pill form even the priciest was substandard so buy the granules on Amazon .​


The difference has been unreal but yes it took like a month , I recently added raw ginger which as you know also works for inflammation after a gentleman here mentioned it and others say it is great .

​

MSM (Methylsulfonylmethane)​


Why do people take MSM?​

People take MSM by mouth or apply it to the skin, mostly using it to lessen inflammation.

They take MSM to try to relieve pain or swelling from:

MSM (Methylsulfonylmethane): Uses and Risks
 
Last edited by a moderator:
I was offered this in it's earliest phases. I did not take it, as I was afraid, and still am, of a drug that lasts a week. Prefer shorter term, after all, who wants a side effect lasting a week instead of a day?
 

StarSong said:
Most people with low BP tend to be thin or no heavier than average weight. Or they have a medical condition like internal bleeding or dehydration.
Click to expand...
Thank you very much for that information. I had no idea. I am dehydrated and anemic and on blood thinners. They will be checking me in March for these conditions. First, have to be checked out to make sure lung cancer has not returned since 2019. I'm a mess. Getting CT scan this Friday, then on to more tests, tests, tests.
 
Pepper said:
Thank you very much for that information. I had no idea. I am dehydrated and anemic and on blood thinners. They will be checking me in March for these conditions. First, have to be checked out to make sure lung cancer has not returned since 2019. I'm a mess. Getting CT scan this Friday, then on to more tests, tests, tests.
Click to expand...
Blood thinners will do it, too. Be careful, hunny - passing out from low BP is no fun. Actually passing out in general is far from a laughing party...
 
My co-worker took one of those drugs, not sure which one but not Ozempic. She looks older and I think too thin. But who am I to judge. After finding out at the first of the year that I would return to full time work starting February, I have lost some weight on my own.

Kelly Osborne is a cute woman. Why did she do this?
 
Good grief, in todays papers, Kelly Osborne.. she's just gone too far. dear oh dear....

95817485-14459511-Kelly_has_been_open_about_her_85lb_postpartum_weight_loss_and_ha-m-61_1741096672076.jpg
95817491-14459511-image-a-40_1741088202225.jpg
 
There is also a new drug yet approved that grows hair on bald heads , its from the UK and yes bald men like myself are interested but would think the company could consider a better ad then the current ad they are now running .

download (11).jpg
 
Michael Z said:
I wouldn't take it. But I generally don't take any prescription meds other than antibiotics as needed. If needed, I would substitute a diet/exercise regimen for any prescription a doctor suggested (other than antibiotics) first before relying on a prescription designed to be taken for life. I do take OTC drugs like ibuprofen, but even that I minimize by consuming over a pound of fresh ginger root each week. I take melatonin, valerian root (for sleep) and saw palmetto, vit D, vit C, and zinc on a regular basis.
Click to expand...
You are a smart man.
I would not take the drug either
 

You must log in or register to reply here.

Back
Top